Nina Khanna Gremmelmaier

Prof. Dr. med.
Nina Khanna Gremmelmaier

Position(s)
Leading Senior Physician, Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel
Research Group Leader, Department of Biomedicine Infection Biology, University of Basel

Institution
University Hospital Basel

Phone +41 61 328 73 25

Email

 

Research Focus

Immunology & Infectious Diseases

Area of Research

Viral and fungal infections, especially in immunocompromised patients. Evaluation of new immune biomarkers and new immunotherapeutic strategies


Approved Research Projects

  • 2020 – 2024 Swiss National Science Foundation. National Center of Competence in Research (NCCR) AntiResist

  • 2018 Bangerter–Rhyner Grant: A Phase I/II single-center study to assess safety and feasibility of virus-specific T cells of 3rd party donors in patients with treatment-refractory viral infections
  • 2018 – 2022 Project Partner Swiss National Science Foundation. Investigator Initiated Clinical Trials (IICT): Using Genetic Risk Factors to Stratify Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
  • 2018 Debiopharm International S.A: Evaluation of Debio 1450 against 24-h biofilm in mouse tissue cage model (combination with: nafcillin, cefazolin, clindamycin, linezolid)
  • 2017 Bangerter–Rhyner Grant: Immune-metabolic changes in neutrophils, monocytes and lymphocytes in patients suffering from gram-negative sepsis
  • 2016 Swiss Transplant Cohort Study. Evolution of mold-specific T cells and NK cells and impact of T-helper 1 Cytokine and Natural Killer (NK) Cell Candidate Genes and on the Development and Outcome of Invasive Mold Infections in Patients after Allogeneic Hematopoietic Stem Cell Transplantation
  • 2013 Commission for Technology and Innovation CTI: "HIT to LEAD to preclinical candidate development of a transcription repressor inhibitory compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci”
  • 2013 Swiss National Science Foundation: Relevance of different CD4+ T cell subsets for antifungal defense. What is aberrant in immunocompromised patients?
  • 2021-2024 University Hospital of Basel: Innovation Focus Cell Therapy
  • 2021 Propatient Research Grant: Third-Party Donor Registry for Personalized antiviral T-cell Immunotherapeutics

    Collaborations

    National Collaborations

    • 2021 – present ESP Working Group, Medical Faculty, University of Basel
    • 2020 – present Scientific Advisory Committee, Propatient – Research Foundation, University Hospital Basel
    • 2020 – present Structural Commission for Professorship of Hematology Stem Cell Research, University of Basel
    • 2020 – present Appeals Committee for Professorship of the Clinical Epidemiology, University of Basel
    • 2019 – present Leader of Clinical Studies and Member of executive board of National Center of Competence in Research (NCCR) AntiResist
    • 2018 – present Subcommission for the Promotion of Young Researchers (= SK2), University of Basel
    • 2017 – present Swisstransplant Arbeitsgruppe Infektiologie (STAI), representative from the USB
    • 2016 – present Scientific Advising for the Swiss Society for Infectious Diseases
    • 2014 – present Advisory boards on Anti-infectives for Pfizer, Switzerland
    • 2013 – present Advisory boards on Anti-infectives for Merck Sharp Dohme, Switzerland
    • 2010 – present Fungal Infection Network of Switzerland (FUNGINOS); President since 2021
    • 2008 – present Infectious Diseases Working Group, Swiss Transplant cohort Study (STCS)
    • 2014 – 2018 Steering Committee of the University Basel Immunology Community (UBICO)
    • 2008 – present Schweizerische Gesellschaft für Infektiologie (SGINF)
    • 2001 – present Schweizerische Medizinische Gesellschaft (FMH)
    • 2021– present Management Team Innovation Focus Cell Therapy

    International Collaborations

    • 2018 – present ESCMID Study Group for Immunocompromised Hosts
    • 2018 – present ESCMID Study Group Fungal Infection Study Group
    • 2018 – present Member of Data safety montoring board for Allecra Therapeutics SAS, France
    • 2017 – present Consultancy on respiratory infection research for Janssen Pharmaceuticals
    • 2014 – present Advisory boards on Antifungals for Gilead Science, DACH (Germany, Austria, CH)
    • 2013 – present European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

    Ongoing Research Projects

    • 2020 – 2024 Swiss National Science Foundation. National Center of Competence in Research (NCCR) AntiResist
    • 2018 – 2022 Project Partner Swiss National Science Foundation. Investigator Initiated Clinical Trials (IICT): Using Genetic Risk Factors to Stratify Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia
    • 2021-2024 University Hospital of Basel: Innovation Focus Cell Therapy
    • 2021 Propatient Research Grant: Third-Party Donor Registry for Personalized antiviral T-cell Immunotherapeutic

      Research Team

      Dr. phil. Rajesh Jayachandran

      Research Fellow

      Phone +41 61 265 21 14
      Email

      Dr. Claudia Stühler

      Postdoctoral Fellow

      Phone +41 61 328 60 17
      Email

      Nathalie Müller

      Doctoral candidate

      Phone +41 61 328 67 45
      Email

      Dr. med. Silvio Ragozzino

      Deputy senior physician

      Phone +41 61 328 58 71
      Email

      Kathrin Ullrich

      Study Nurse

      Phone +41 61 328 60 59
      Email

      Delphine Cornillet

      Student

      Phone +41 61 265 23 23
      Email

      Dr. Anne-Kathrin Woischnig

      Research Fellow

      Phone +41 61 265 23 23
      Email

      Darya Palianina

      PhD Student

      Phone +41 61 265 23 66
      Email